[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ma et al., 2020 - Google Patents

Structure-guided discovery of a single-domain antibody agonist against human apelin receptor

Ma et al., 2020

View HTML @Full View
Document ID
1321939421602052014
Author
Ma Y
Ding Y
Song X
Ma X
Li X
Zhang N
Song Y
Sun Y
Shen Y
Zhong W
Hu L
Ma Y
Zhang M
Publication year
Publication venue
Science advances

External Links

Snippet

Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chronic heart failure. Here, we report the structure- guided discovery of a single-domain antibody (sdAb) agonist JN241-9, based on the …
Continue reading at www.science.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Similar Documents

Publication Publication Date Title
Ma et al. Structure-guided discovery of a single-domain antibody agonist against human apelin receptor
Maeda et al. Development of an antibody fragment that stabilizes GPCR/G-protein complexes
Hutchings et al. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Asada et al. Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog
JP6164535B2 (en) GPCR: Binding domain generated for G protein complex and uses derived therefrom
Webb et al. Opportunities for functional selectivity in GPCR antibodies
Schmitz et al. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains
Miles et al. Viral GPCR US28 can signal in response to chemokine agonists of nearly unlimited structural degeneracy
US20210340249A1 (en) Muscarinic acetylcholine receptor binding agents and uses thereof
Vij et al. A targeted boost-and-sort immunization strategy using Escherichia coli BamA identifies rare growth inhibitory antibodies
Vahedi et al. Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein
Ayoub et al. Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges
Szykowska et al. Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain
Salazar et al. Antibody Therapies Targeting Complex Membrane Proteins
Sun et al. Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8
Yu et al. Structural basis of μ-opioid receptor-targeting by a nanobody antagonist
Sonawani et al. Insights into the dynamic interactions at chemokine-receptor interfaces and mechanistic models of chemokine binding
Ge et al. An epitope-directed selection strategy facilitating the identification of Frizzled receptor selective antibodies
Xi et al. A novel shark single-domain antibody targeting OGT as a tool for detection and intracellular localization
Pao et al. Structural basis of an epitope tagging system derived from Haloarcula marismortui bacteriorhodopsin I D94N and its monoclonal antibody GD‐26
Nie et al. Production and characterization of polyclonal and monoclonal antibodies of lamprey pore-forming protein
Peterson et al. Discovery and design of G protein-coupled receptor targeting antibodies
Salom et al. The Impact of Nanobodies on G Protein–Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents
Solt Investigating the molecular signatures of β1-adrenergic receptor activation
Salazara et al. Antibody Therapies Targeting Complex Membrane Proteins